DNA test-maker warned to halt sales
WASHINGTON — The Food and Drug Administration has ordered Google-backed genetic test maker 23andMe to halt sales of its personalized DNA test kits, saying the company has failed to show that the technology is supported by science.
In a warning letter posted online on Monday, FDA regulators say that the Silicon Valley company has not shown that its tests are safe or effective despite “more than 14 face-to-face and teleconference meetings” and “hundreds of email exchanges.” The agency ordered 23andMe to stop marketing its test immediately, warning that erroneous results could cause customers to seek unnecessary or ineffective medical care.
The 23andMe saliva-based test kit, released more than five years ago, claims to tell customers if they are at risk for more than 250 diseases and health conditions. The FDA says only medical tests cleared by the government may make such claims.
The letter follows years of back-and-forth between the government and 23andMe, the most visible company among a field of startups selling personal genetic information. Doctors and health officials worry that the products are built on flimsy science.
For years, 23andMe resisted regulation, arguing that it provides consumers with information, not a medical service. But last year, the company changed course, submitting several of the disease-specific tests included in its test kit.
The FDA warning, dated Nov. 22, takes issue with a number of claims the company makes for its test kit, particularly calling it a “first step in prevention” against diseases such as diabetes, heart disease and breast cancer.
Regulators worry that false results from the test could cause patients to receive inadequate or inappropriate medical care. For instance, 23andMe says its test can identify women who carry the BRCA gene mutation that significantly increases the risk of breast and ovarian cancer. But a false result could lead women to undergo unnecessary screening, chemotherapy and surgery.
The FDA gives the company 15 days to respond in writing to its concerns. Warning letters are not legally binding, but the government can take companies to court if they are ignored.
23andMe was co-founded by Anne Wojcicki, who recently separated from her husband, Google co-founder Sergey Brin. Both Google and Brin have invested millions in the privately held company.
The FDA regulates genetic tests administered by medical providers. The FDA's concern with 23andMe centers on its marketing, which skirts doctors and health professionals.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Education tech firm Acrobatiq does software to supplement college learning
- Chesapeake Energy appoints Brad Martin chairman of the board
- CMU showcases its lengthy list of fledgling companies at venture event
- Safety of credit cards up to banks
- Tesla investors leery as shares, targets plummet
- As craft fades, personal touch helps Northway Shoes & Repair thrive
- Budweiser brewer AB InBev wants to take over SABMiller for $108.2B
- 2 Marcellus pipeline projects move forward
- Wabtec buying Australian sensor maker Track IQ
- Kombucha producers resist call to indicate alcohol content on labels
- Class action lawsuit in California seeks Volkswagen buyback